Clinical Trials Logo

Carcinoma, Renal Cell clinical trials

View clinical trials related to Carcinoma, Renal Cell.

Filter by:

NCT ID: NCT00445042 Completed - Clinical trials for Carcinoma, Renal Cell

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

Start date: November 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and toxicity levels of Dose Escalated Sorafenib in the treatment of patients with renal cancer.

NCT ID: NCT00444314 Completed - Clinical trials for Metastatic Renal Cell Carcinoma

Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

Start date: February 2007
Phase: Phase 2
Study type: Interventional

This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and pharmacodynamics, of Panzem® NCD with or without Sunitinib Malate in patients with metastatic renal cell carcinoma progressing on Sunitinib Malate.

NCT ID: NCT00441337 Completed - Prostate Cancer Clinical Trials

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

MDX1106-01
Start date: August 2006
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or hormone refractory prostate cancer

NCT ID: NCT00428220 Completed - Clinical trials for Non-Small Cell Lung Cancer

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Start date: July 2007
Phase: N/A
Study type: Interventional

This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.

NCT ID: NCT00425386 Completed - Kidney Cancer Clinical Trials

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Start date: August 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Sunitinib and erlotinib may stop the growth of tumor cell by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying the best dose of erlotinib when given together with sunitinib and to see how well they work in treating patients with unresectable or metastatic kidney cancer.

NCT ID: NCT00425204 Completed - Prostate Cancer Clinical Trials

Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

Start date: March 2004
Phase: Phase 2
Study type: Interventional

A multi-center, open-label, extended treatment, clinical trial examining the safety of administering multiple does of panitumumab by intravenous (i.v.) infusion to patients who have previously received panitumumab and benefited from treatment

NCT ID: NCT00425035 Completed - Clinical trials for Advanced Renal Cell Carcinoma

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

Start date: February 2003
Phase: Phase 2
Study type: Interventional

Multicenter, 2-part, multiple-dose study designed to evaluate the safety and effectiveness of weekly administration of panitumumab in subjects with renal carcinoma. Part 1 was initiated in 2001 and will not be presented here. Part 2 was designed to examine a dose of 2.5 mg/kg/wk in 2 cohorts.

NCT ID: NCT00422786 Completed - Clinical trials for Carcinoma, Renal Cell

Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma

Start date: March 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of CAP-232 in the treatment of patients with previously treated (refractory) renal cell carcinoma

NCT ID: NCT00422344 Completed - Clinical trials for Renal Cell Carcinoma

A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma

Start date: October 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of RAD-001 and Sunitinib given in combination for renal cell cancer. We also want to find out what effects (good and bad) the combination of RAD-001 and Sunitinib have on you and your tumor. RAD001 is a pill that works by shutting down some of the pathways in the cell that make tumors grow. Sunitinib is a pill that works by shutting off the signal in the cancer cells that tell the cells to grow blood vessels. Without this signal, the blood vessels to the tumors shrink down.

NCT ID: NCT00422019 Completed - Clinical trials for Advanced Renal Cell Carcinoma

A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

Start date: January 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of AMG 102 in patients with Advanced Renal Cancer.